Recognising severe cutaneous adverse drug reactions

Chee, Paul

doi:10.5694/mja17.00522

Topics

Severe cutaneous adverse drug reactions (SCARs) are a major cause of morbidity and mortality in Australia and recognition is important. Key diagnostic features are present early in the presentation and common drug associations exist. Clinicians should become familiar with these reaction patterns to more effectively manage these dermatological emergencies.

John Hunter Hospital, Newcastle, NSW

Correspondence: paulchee@bigpond.com

Series editors:

Balakrishnan (Kichu) Nair

Simon O'Connor

Competing interests:

No relevant disclosures.

1. Chung WH, Wang CW, Dao RL. Severe cutaneous adverse drug reactions. J Dermatol 2016; 43: 758-766.
2. Dibek ME, Guvenir H, Bahceci S, et al. Severe cutaneous adverse drug reactions in pediatric patients: a multicenter study. J Allergy Clin Immunol Pract 2017; 5: 757-763.
3. Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther 2010; 88: 60-68.
4. Kardaun SH, Sekula P, Valeyrie-Allanore L, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol 2013; 169: 1071-1080.
5. Sidoro A, Halevy S, Bavinck JN, et al. Acute generalized exanthematous pustulosis (AGEP) — a clinical reaction pattern. J Cutan Pathol 2001; 28: 113-119.

Online responses are no longer available. Please refer to our instructions for authors page for more information.